Humacyte (NASDAQ:HUMA) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Humacyte (NASDAQ:HUMA) posted its quarterly earnings results on Friday. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.01, Yahoo Finance reports. During the same quarter last year, the business posted ($0.21) EPS.

Humacyte Trading Down 8.1 %

Shares of NASDAQ HUMA opened at $3.31 on Friday. Humacyte has a twelve month low of $1.96 and a twelve month high of $5.60. The firm has a fifty day simple moving average of $3.50 and a 200 day simple moving average of $3.00. The company has a debt-to-equity ratio of 0.46, a current ratio of 6.79 and a quick ratio of 6.79.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on HUMA. HC Wainwright began coverage on shares of Humacyte in a research report on Monday, December 11th. They issued a “buy” rating and a $6.00 target price on the stock. Benchmark cut their target price on shares of Humacyte from $16.00 to $15.00 and set a “buy” rating on the stock in a research report on Wednesday, December 27th.

Institutional Investors Weigh In On Humacyte

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Ensign Peak Advisors Inc acquired a new position in shares of Humacyte during the first quarter valued at about $56,000. American International Group Inc. acquired a new position in shares of Humacyte during the second quarter valued at about $27,000. UBS Group AG grew its holdings in shares of Humacyte by 92.0% during the third quarter. UBS Group AG now owns 9,827 shares of the company’s stock valued at $32,000 after buying an additional 4,710 shares during the last quarter. Mirabella Financial Services LLP acquired a new position in shares of Humacyte during the first quarter valued at about $72,000. Finally, Eudaimonia Partners LLC acquired a new position in shares of Humacyte during the first quarter valued at about $73,000. 27.36% of the stock is owned by institutional investors.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs).